The Efficacy of Endovascular Treatment in FPOD With TASC C and D Lesions
The Efficacy of Endovascular Treatment in FPOD With TASC C and D Lesions
Based on the development of new tools, including drug coated balloon, paclitaxel eluting
 stent, interwoven stents, debulking tools, more challenging femoropopliteal arterial lesions
 have been treated with endovascular procedures.

 The TASC D lesion ,especially with popliteal artery involved are often excluded in
 prospective clinical trials. Therefore, a well-designed real world study that track clinical
 relevant outcomes, are required to determine the optimal therapies for patients with complex
 femoropopliteal lesions.
According to the TASC II guidelines, TASC D lesions was recommended for primary endovascular
 revascularization, TASC C lesions for surgical revascularization in patients with appropriate
 perioperative risk and available conduit. However, Based on the development of new tools,
 including drug coated balloon, paclitaxel eluting stent, interwoven stents, debulking tools,
 more challenging femoropopliteal arterial lesions have been treated with endovascular
 procedures.

 Despite The shift of Endovascular- first strategy has been documented in recent literature.
 There still lack evidence to support either approach have a significant advantage over the
 other. And TASC D lesion ,especially with popliteal artery involved are often excluded in
 prospective clinical trials. Therefore, a well-designed real world study that track clinical
 relevant outcomes, are required to determine the optimal therapies for patients with complex
 femoropopliteal lesions.
Inclusion Criteria:

 1. Patients over 18 years old

 2. Patients with Rutherford classification range from 3 to 6

 3. If patients with both lower limbs meeting the inclusion criteria, both side of limb
 can be selected for this study

 4. The lower extremity artery needs to have a healthy runoff of no less than 10 cm above
 the ankle, and at least one healthy dorsalis pedis artery, medial or lateral plantar
 artery connected with the digital artery below the ankle

 5. The guide wire should pass through the lesion of femoropopliteal artery, and further
 endovascular treatment is performed. In this study, we did not limit the methods of
 the guide wire passing through the target lesion

 6. If the first-time endovascular treatment is failure, patients undergo endovascular
 treatment successfully at the second time, the patients can still be enrolled

 7. For patients with aortoiliac artery lesions, they can be enrolled after the successful
 reconstruction of aortoiliac artery

 8. Informed consent signed by patients

 Exclusion Criteria:

 1. Patients who are unwilling or refuse to sign the informed consent form

 2. Patients with acute and subacute lower extremity arterial thrombosis or arterial
 embolism

 3. Patients with thromboangiitis obliterans

 4. Patients with failure of endovascular treatment, and transferred to bypass surgery

 5. Patients who underwent surgical atherectomy for common femoral artery occlusive
 lesions

 6. Patients with known allergy to heparin, low molecular weight heparin and contrast
 agents

 7. Patients who have been enrolled in other clinical trials in the past 3 months

 8. Women during pregnancy and lactation

 9. Patients with other diseases that may lead to difficulties in the trial or
 significantly shorten the life expectancy (< 3 years), such as tumors, severe liver
 disease, cardiac insufficiency